Harmony Biosciences Holdings, Inc. P/E Ratio 2019–2025
Harmony Biosciences Holdings, Inc. reported 13.81 of price-to-earnings ratio for fiscal 2025. That was 0.7% higher than fiscal 2024. Compared with fiscal 2021, the change was -81.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 13.81 | +0.7% |
| FY 2024 | 13.71 | -9.6% |
| FY 2023 | 15.16 | -18.3% |
| FY 2022 | 18.55 | -74.8% |
| FY 2021 | 73.52 | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
Source: Harmony Biosciences Holdings, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open HRMY 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Harmony Biosciences Holdings, Inc. reported 13.81 of price-to-earnings ratio for fiscal 2025. That was 0.7% higher than fiscal 2024. Compared with fiscal 2021, the change was -81.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Harmony Biosciences Holdings, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHarmony Biosciences Holdings, Inc. — frequently asked questions
What is Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio?
Harmony Biosciences Holdings, Inc. (HRMY) reported price-to-earnings ratio of 13.81 for fiscal year 2025, per its SEC filings.
How has Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2019 and 2025, HRMY's price-to-earnings ratio declined at roughly 24.3% per year (compound annual rate), from 73.52 to 13.81.
Where does this data come from?
Figures are computed from Harmony Biosciences Holdings, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More HRMY financial history
Full HRMY fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →